Amylyx Pharmaceuticals (AMLX) Accounts Payables (2021 - 2026)
Amylyx Pharmaceuticals (AMLX) posted quarterly Accounts Payables of $3.5 million for Q1 2026, down 26.63% year-over-year from $4.8 million in Q1 2025, and little changed quarter-over-quarter from $3.5 million in Q4 2025.
Amylyx Pharmaceuticals (AMLX) Accounts Payables (2021 - 2026) Analysis & Trends
Amylyx Pharmaceuticals' Accounts Payables history runs 6 years deep, the most recent figure standing at $3.5 million for Q1 2026.
- In Q1 2026, Accounts Payables fell 26.63% year-over-year to $3.5 million; the TTM figure through Mar 2026 stood at $3.5 million (down 26.63% YoY), while the FY2025 annual figure was $3.5 million, up 19.73% from the prior year.
- Accounts Payables for Q1 2026 stood at $3.5 million, roughly flat from $3.5 million in the prior quarter.
- The five-year high for Accounts Payables was $24.7 million in Q2 2023, with the low at $1.5 million in Q3 2024.
- The 5-year median for Accounts Payables is $6.3 million (2022), against an average of $8.6 million.
- The sharpest annual moves came in 2024 and 2025: Accounts Payables sank 86.68% in 2024, then soared 259.05% in 2025.
- Amylyx Pharmaceuticals' Accounts Payables stood at $6.3 million in 2022, then surged by 252.58% to $22.1 million in 2023, then tumbled by 86.68% to $2.9 million in 2024, then rose by 19.73% to $3.5 million in 2025, then gained by 0.28% to $3.5 million in 2026.
- Business Quant data shows AMLX's Accounts Payables at $3.5 million in Q1 2026, $3.5 million in Q4 2025, and $5.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.80 Bn | - | -5.09 Bn |
| 2 | Teva Pharmaceutical Industries | 43.05 Bn | 39.39 Bn | 2.15 Bn | 2.72 Bn |
| 3 | Zoetis | 31.51 Bn | 29.84 Bn | 1.05 Bn | 452.00 Mn |
| 4 | Takeda Pharmaceutical | 28.70 Bn | 22.90 Bn | 5.10 Bn | 2.80 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 497.80 Mn |
| 6 | Viatris | 18.83 Bn | 17.95 Bn | 1.46 Bn | 1.73 Bn |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | 808.30 Mn |
| 8 | Elanco Animal Health | 12.06 Bn | 11.53 Bn | 798.00 Mn | 427.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | 356.00 Mn |
| 10 | Amylyx Pharmaceuticals | 4.34 Bn | 4.34 Bn | - | 5.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.53 Mn |
| Mar 31, 2026 | 3.53 Mn |
| Dec 31, 2025 | 3.52 Mn |
| Sep 30, 2025 | 5.34 Mn |
| Jun 30, 2025 | 3.29 Mn |
| Mar 31, 2025 | 4.81 Mn |
| Dec 31, 2024 | 2.94 Mn |
| Sep 30, 2024 | 1.49 Mn |
| Jun 30, 2024 | 4.96 Mn |
| Mar 31, 2024 | 21.45 Mn |
| Dec 31, 2023 | 22.06 Mn |
| Sep 30, 2023 | 6.37 Mn |
| Jun 30, 2023 | 24.70 Mn |
| Mar 31, 2023 | 10.77 Mn |
| Dec 31, 2022 | 6.26 Mn |
| Sep 30, 2022 | 7.05 Mn |
| Jun 30, 2022 | 8.12 Mn |
| Mar 31, 2022 | 10.05 Mn |
| Dec 31, 2021 | 4.37 Mn |